Skip to content

Efficacy and Safety of Finerenone in Kidney Transplant Recipients with Proteinuria: A Retrospective Study

Efficacy and Safety of Finerenone in Kidney Transplant Recipients with Proteinuria: A Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094514
Enrollment
Unknown
Registered
2024-12-24
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal transplantion

Interventions

Kidney transplant patients with proteinuria receiving Finerenone:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18; 2. First renal transplant, time from transplantation >= 3 months; 3. Patients who are routine visitors to the outpatient clinics for follow-ups at West China Hospital of Sichuan University; 4. Urinary albumin-to-creatinine ratio (UACR) between 30 mg/g and 5000 mg/g; 5. Stable renal function, with an eGFR >= 25 mL/min/1.73^2 and a decrease in eGFR <25% from baseline over the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes mellitus; 2. Preparation for pregnancy, pregnancy, or lactation,; 3. With malignant tumors or serious organ dysfunction; 4. History of recurrent or persistent hypotension, or shock; 5. Severe hypoglycemia within the past 3 months or have had episodes of unconsciousness due to hypoglycemia; 6. Recurrent urinary tract infections or genital infections within the past 6 months; 7. Severe peripheral vascular disease (i.e, history of amputation, gangrene, non-healing ulcers, ischemic rest pain); 8. Urinary albumin-to-creatinine ratio (UACR) >5000 mg/g; 9. Renal artery stenosis in transplanted kidney; 11. Stroke, transient ischemic attack, myocardial infarction, or unstable angina within the 12 weeks; 12. With concomitant autoimmune diseases such as systemic lupus erythematosus or ANCA-associated vasculitis; 13. Abnormal liver function (AST or ALT > 3 times upper limit of normal; or total bilirubin > 2 times upper limit of normal); 14. Participation in other clinical trials; 15. Comorbidities with a prognosis of less than 2 years life expectancy.

Design outcomes

Primary

MeasureTime frame
Urinary albumin-to-creatinine ratio (UACR);Urinary protein-to-creatinine ratio (PCR);24-hour urinary protein quantification;Serum creatinine;EGFR;Tacrolimus trough concentration;Serum electrolytes;Fasting blood glucose;Lipid profile;Urine glucose;Urine white blood cell count;Urinary bacterial count;Liver function;Full blood count;AEs;Urine red blood cell count;

Countries

China

Contacts

Public ContactYunying Shi

West China Hospital, Sichuan University, Chengdu, Sichuan, China

shiyunying@wchscu.edu.cn+86 189 8060 5862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026